{"id":28361,"date":"2025-01-08T22:57:00","date_gmt":"2025-01-08T14:57:00","guid":{"rendered":"https:\/\/flcube.com\/?p=28361"},"modified":"2025-03-03T15:29:49","modified_gmt":"2025-03-03T07:29:49","slug":"duality-biologics-and-avenzo-ink-exclusive-license-for-db-1418-avzo-1418","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=28361","title":{"rendered":"Duality Biologics and Avenzo Ink Exclusive License for DB-1418\/AVZO-1418"},"content":{"rendered":"\n

On January 8, Duality Biologics, Inc. (Duality Bio) and Avenzo Therapeutics, Inc. (Avenzo) jointly announced that they have entered into an exclusive license agreement. Under the agreement, Avenzo will obtain exclusive rights to develop, manufacture, and commercialize DB-1418\/AVZO-1418 globally, excluding Greater China. DB-1418\/AVZO-1418 is an EGFR\/HER3 bispecific antibody-drug conjugate (ADC) developed by Duality Bio.<\/p>\n\n\n\n

Agreement Details<\/strong>
The licensing agreement grants Avenzo the exclusive rights to further develop and commercialize DB-1418\/AVZO-1418 outside Greater China. This collaboration aims to leverage Avenzo’s expertise in drug development and commercialization to bring the potential benefits of DB-1418\/AVZO-1418 to patients worldwide.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

On January 8, Duality Biologics, Inc. (Duality Bio) and Avenzo Therapeutics, Inc. (Avenzo) jointly announced…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[1721,232,3795],"class_list":["post-28361","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-avenzo-therapeutics","tag-duality-biologics","tag-duality-biotherapeutics"],"yoast_head":"\nDuality Biologics and Avenzo Ink Exclusive License for DB-1418\/AVZO-1418 - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"On January 8, Duality Biologics, Inc. (Duality Bio) and Avenzo Therapeutics, Inc. (Avenzo) jointly announced that they have entered into an exclusive license agreement. Under the agreement, Avenzo will obtain exclusive rights to develop, manufacture, and commercialize DB-1418\/AVZO-1418 globally, excluding Greater China. DB-1418\/AVZO-1418 is an EGFR\/HER3 bispecific antibody-drug conjugate (ADC) developed by Duality Bio.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=28361\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Duality Biologics and Avenzo Ink Exclusive License for DB-1418\/AVZO-1418\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=28361\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-08T14:57:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-03T07:29:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28361#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28361\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Duality Biologics and Avenzo Ink Exclusive License for DB-1418\\\/AVZO-1418\",\"datePublished\":\"2025-01-08T14:57:00+00:00\",\"dateModified\":\"2025-03-03T07:29:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28361\"},\"wordCount\":114,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Avenzo Therapeutics\",\"Duality Biologics\",\"Duality Biotherapeutics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=28361#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28361\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=28361\",\"name\":\"Duality Biologics and Avenzo Ink Exclusive License for DB-1418\\\/AVZO-1418 - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2025-01-08T14:57:00+00:00\",\"dateModified\":\"2025-03-03T07:29:49+00:00\",\"description\":\"On January 8, Duality Biologics, Inc. (Duality Bio) and Avenzo Therapeutics, Inc. (Avenzo) jointly announced that they have entered into an exclusive license agreement. Under the agreement, Avenzo will obtain exclusive rights to develop, manufacture, and commercialize DB-1418\\\/AVZO-1418 globally, excluding Greater China. DB-1418\\\/AVZO-1418 is an EGFR\\\/HER3 bispecific antibody-drug conjugate (ADC) developed by Duality Bio.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28361#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=28361\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28361#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Duality Biologics and Avenzo Ink Exclusive License for DB-1418\\\/AVZO-1418\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Duality Biologics and Avenzo Ink Exclusive License for DB-1418\/AVZO-1418 - Insight, China's Pharmaceutical Industry","description":"On January 8, Duality Biologics, Inc. (Duality Bio) and Avenzo Therapeutics, Inc. (Avenzo) jointly announced that they have entered into an exclusive license agreement. Under the agreement, Avenzo will obtain exclusive rights to develop, manufacture, and commercialize DB-1418\/AVZO-1418 globally, excluding Greater China. DB-1418\/AVZO-1418 is an EGFR\/HER3 bispecific antibody-drug conjugate (ADC) developed by Duality Bio.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=28361","og_locale":"en_US","og_type":"article","og_title":"Duality Biologics and Avenzo Ink Exclusive License for DB-1418\/AVZO-1418","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=28361","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-01-08T14:57:00+00:00","article_modified_time":"2025-03-03T07:29:49+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=28361#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=28361"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Duality Biologics and Avenzo Ink Exclusive License for DB-1418\/AVZO-1418","datePublished":"2025-01-08T14:57:00+00:00","dateModified":"2025-03-03T07:29:49+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=28361"},"wordCount":114,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Avenzo Therapeutics","Duality Biologics","Duality Biotherapeutics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=28361#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=28361","url":"https:\/\/flcube.com\/?p=28361","name":"Duality Biologics and Avenzo Ink Exclusive License for DB-1418\/AVZO-1418 - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2025-01-08T14:57:00+00:00","dateModified":"2025-03-03T07:29:49+00:00","description":"On January 8, Duality Biologics, Inc. (Duality Bio) and Avenzo Therapeutics, Inc. (Avenzo) jointly announced that they have entered into an exclusive license agreement. Under the agreement, Avenzo will obtain exclusive rights to develop, manufacture, and commercialize DB-1418\/AVZO-1418 globally, excluding Greater China. DB-1418\/AVZO-1418 is an EGFR\/HER3 bispecific antibody-drug conjugate (ADC) developed by Duality Bio.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=28361#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=28361"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=28361#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Duality Biologics and Avenzo Ink Exclusive License for DB-1418\/AVZO-1418"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/28361","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=28361"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/28361\/revisions"}],"predecessor-version":[{"id":28362,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/28361\/revisions\/28362"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=28361"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=28361"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=28361"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}